Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Decernotinib, Subcutaneous Methotrexate Drug Updates, Trials, Approvals

Michele B. Kaufman, PharmD, BCGP  |  Issue: October 2014  |  October 1, 2014

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:drugFDAInjectionKaufmanMethotrexateResearchRheumatoid arthritisrheumatologistSafetyTofacitinib

Related Articles

    Biosimilar for Infliximab Launched in Europe

    April 1, 2015

    Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information

    Drug Updates

    September 1, 2010

    Information on New Approvals and Medication Safety

    FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children

    May 16, 2017

    The FDA has approved a new formulation of methotrexate designed as an oral solution for pediatric patients. The agency has also recently introduced age restrictions for codeine and tramadol for children under age 12, citing their risks for slowed or difficult breathing and death…

    IV Tramadol Promising for Postoperative Pain; FDA Denies IV Meloxicam Approval

    July 2, 2018

    In its first phase 3 clinical trial, intravenous tramadol has met its primary endpoint for relieving postoperative pain…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences